公开(公告)号：US20250011454A1

公开(公告)日：2025-01-09

申请号：US18703264

申请日：2022-10-19

Applicant: Janssen Biotech, Inc.

Inventor： Adam ZWOLAK ,  Jason HO ,  James TESTA, Jr. ,  Michael Riis HANSEN ,  Xiefan LIN-SCHMIDT ,  Ian WHITE ,  Sanjaya SINGH

IPC: C07K16/28 ,  C07K16/30

Abstract: Provided herein, in certain aspects, is a binding molecule comprising an antigen binding domain and an Fc region; wherein the antigen binding domain is monovalent and the Fc region comprises K248E and T437R mutations (RE mutations), wherein amino acid residue numbering is according to the EU numbering system; wherein the binding molecule has increased capability of hexamerization on a cell surface, and/or increased capability of engaging C1q.

公开(公告)号：US20220033522A1

公开(公告)日：2022-02-03

申请号：US17391744

申请日：2021-08-02

Applicant: JANSSEN BIOTECH, INC.

Inventor： Rajkumar GANESAN ,  Adam ZWOLAK ,  Ian WHITE ,  Ninkka TAMOT ,  Paul B. HARVILLA ,  Rajitha DODDAREDDY ,  Sanjaya SINGH ,  Martin Jack BORROK III

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/10

Abstract: Provided herein are multispecific molecules comprising a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR) and a second binding domain that specifically binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related methods for the treatment of patients infected with SARS-CoV-2.